Skip to site menu Skip to page content

Fast and Flexible: Early Phase Manufacturing, European Biopharmaceutical Review

By Patheon

By Jon Sutch, PhD

Early stage manufacturers of oral solid dosage forms need to be fast and flexible to generate development pathways that can cope with variable API characteristics, as well as highly potent molecules.

Technology, risk assessment, quality by design and scale-up to later-phase studies are all in the mix of considerations.

No two early development projects are alike. The active pharmaceutical ingredient (API) properties will differ, from the potency to the physical characteristics; the clinical plans will vary, from the locations, to the study centres, to the design of the study itself.

Download to read more.

This article originally appeared in European Biopharmaceutical Review.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content